BioMarin Pharmaceutical I... (BMRN)
58.67
-0.50 (-0.85%)
At close: Apr 21, 2025, 3:59 PM
58.77
0.18%
Pre-market: Apr 22, 2025, 04:13 AM EDT
BioMarin Pharmaceutical Revenue Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | 735.63M | 733.87M | 702.13M | 637.82M | 633.15M | 568.27M | 584.7M | 586.43M | 525.49M | 493.35M | 517.66M | 505.52M | 435.22M | 393.84M | 486.67M | 18.26M | 437.05M | 16.04M | 10.45M | 489.04M | 436.58M | 450.9M | 379.07M | 394.48M | 6.06M | 386.32M | 367.79M |
| Product Revenue Growth | +0.24% | +4.52% | +10.08% | +0.74% | +11.42% | -2.81% | -0.29% | +11.60% | +6.52% | -4.70% | +2.40% | +16.15% | +10.51% | -19.07% | +2565.08% | -95.82% | +2624.21% | +53.48% | -97.86% | +12.02% | -3.17% | +18.95% | -3.91% | +6406.40% | -98.43% | +5.04% | n/a |
| Royalty And Other Revenue | 11.68M | 11.87M | 9.9M | 11.02M | 13.06M | 13.06M | 10.58M | 9.99M | 12.05M | 12M | 16.14M | 13.83M | 14.59M | 14.9M | 15.02M | n/a | 15.07M | n/a | n/a | 13.03M | 17.86M | n/a | n/a | n/a | n/a | n/a | n/a |
| Royalty And Other Revenue Growth | -1.63% | +19.93% | -10.15% | -15.63% | -0.03% | +23.50% | +5.89% | -17.08% | +0.42% | -25.67% | +16.65% | -5.19% | -2.09% | -0.81% | n/a | n/a | n/a | n/a | n/a | -27.06% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
|---|---|---|---|---|---|---|---|
| Europe Revenue | 518.47M | 509.19M | 436.43M | 301.49M | 252.63M | 178.75M | 139.94M |
| Europe Revenue Growth | +1.82% | +16.67% | +44.76% | +19.34% | +41.34% | +27.73% | n/a |
| Latin America Revenue | 205.86M | 218.79M | 185.05M | 182.44M | 147.47M | 142.31M | 118.56M |
| Latin America Revenue Growth | -5.91% | +18.24% | +1.43% | +23.71% | +3.63% | +20.03% | n/a |
| Rest Of World Revenue | 223.75M | 197.63M | 172.94M | 241.48M | 209.21M | 124.77M | 112.49M |
| Rest Of World Revenue Growth | +13.22% | +14.28% | -28.38% | +15.42% | +67.68% | +10.91% | n/a |
| United States Revenue | 912.38M | 778.44M | 696.79M | 588.24M | 507.54M | n/a | n/a |
| United States Revenue Growth | +17.21% | +11.72% | +18.45% | +15.90% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 266.61M | 253.48M | 276.65M | 222.51M | 275.02M | 231.4M | 216.78M | 218.38M | 245.74M | 216.82M | 196.84M | 194.62M | 217.56M | 183.33M | 184.16M | 174.32M | 195.51M | 179.45M | 175.41M | 187.29M | 187.9M | 170.11M | 160.75M | 162.16M | 164.17M | 148.57M | 153.28M | 138.34M | 160.28M | 130.53M | 143.5M | 120.02M | 142.96M | 118.76M | 109.58M | 105.3M | 113.91M | 94.04M | 101.51M | 92.81M |
| Selling, General, and Administrative Revenue Growth | +5.18% | -8.38% | +24.34% | -19.10% | +18.85% | +6.74% | -0.73% | -11.13% | +13.34% | +10.15% | +1.14% | -10.55% | +18.67% | -0.45% | +5.65% | -10.84% | +8.95% | +2.30% | -6.34% | -0.32% | +10.46% | +5.82% | -0.87% | -1.23% | +10.50% | -3.08% | +10.80% | -13.69% | +22.79% | -9.04% | +19.57% | -16.05% | +20.38% | +8.38% | +4.06% | -7.56% | +21.12% | -7.36% | +9.38% | n/a |
| Research and Development Revenue | 173.51M | 184.9M | 183.79M | 204.99M | 206.25M | 191.31M | 177.36M | 171.85M | 172.75M | 157.83M | 158.19M | 160.84M | 161.09M | 157.87M | 161.11M | 148.72M | 156.67M | 147.05M | 182.14M | 142.26M | 172.81M | 172.96M | 185.64M | 183.59M | 175.39M | 161.41M | 175.58M | 183.95M | 168.61M | 154.1M | 143.04M | 145M | 175.24M | 160.83M | 167.04M | 158.79M | 176.12M | 158.71M | 157.9M | 142.07M |
| Research and Development Revenue Growth | -6.16% | +0.61% | -10.34% | -0.61% | +7.81% | +7.87% | +3.21% | -0.52% | +9.45% | -0.23% | -1.65% | -0.16% | +2.04% | -2.01% | +8.33% | -5.07% | +6.54% | -19.26% | +28.04% | -17.68% | -0.09% | -6.83% | +1.12% | +4.68% | +8.66% | -8.07% | -4.55% | +9.10% | +9.41% | +7.73% | -1.35% | -17.26% | +8.96% | -3.72% | +5.19% | -9.84% | +10.97% | +0.51% | +11.14% | n/a |